new_0222_0505|FNCH|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0505|FNCH|1|Finch Therapeutics Group Inc Total Current Assets (Quarterly) (USD)|Finch Therapeutics Group Inc Cash and Short Term Investments (Quarterly) (USD)|Finch Therapeutics Group Inc Inventories (Quarterly) (USD)|Finch Therapeutics Group Inc Net PP&E (Quarterly) (USD)|Finch Therapeutics Group Inc Goodwill and Intangibles (Quarterly) (USD)|Finch Therapeutics Group Inc Total Liabilities (Quarterly) (USD)|Finch Therapeutics Group Inc Total Current Liabilities (Quarterly) (USD)|Finch Therapeutics Group Inc Total Long Term Liabilities (Quarterly) (USD)|Finch Therapeutics Group Inc Total Deposits (Quarterly) (USD)|Finch Therapeutics Group Inc Book Value (Quarterly) (USD)|Finch Therapeutics Group Inc Retained Earnings (Quarterly) (USD)|Finch Therapeutics Group Inc Treasury Stock (Quarterly) (USD)|Finch Therapeutics Group Inc EV to Revenues|Finch Therapeutics Group Inc EV to Earnings|Finch Therapeutics Group Inc EV to Free Cash Flow|Finch Therapeutics Group Inc EV to Assets (Quarterly)|Finch Therapeutics Group Inc PS Ratio|Finch Therapeutics Group Inc PE Ratio|Finch Therapeutics Group Inc Price to Book Value|Finch Therapeutics Group Inc PEG Ratio|Finch Therapeutics Group Inc Debt to Equity Ratio|Finch Therapeutics Group Inc Dividend Yield|Finch Therapeutics Group Inc Shareholder Yield (TTM)|Finch Therapeutics Group Inc Percent of Shares Outstanding Short|Finch Therapeutics Group Inc Total Receivables (Quarterly) (USD)|Finch Therapeutics Group Inc Total Payables (Quarterly) (USD)|Finch Therapeutics Group Inc Total Capital Stock (Quarterly) (USD)|Finch Therapeutics Group Inc Return on Invested Capital|Finch Therapeutics Group Inc Quality Ratio Score|Finch Therapeutics Group Inc Momentum Score|Finch Therapeutics Group Inc Beta (1Y)|Finch Therapeutics Group Inc Sustainable Growth Rate (TTM)|Finch Therapeutics Group Inc Institutional Investor Ownership Percentage|Finch Therapeutics Group Inc Average Diluted Shares Outstanding (Quarterly)|Finch Therapeutics Group Inc Total Employees (Annual)|Finch Therapeutics Group Inc EPS Diluted (Quarterly) (USD)|Finch Therapeutics Group Inc SG&A Expense (Quarterly) (USD)|Finch Therapeutics Group Inc Shares Outstanding|Finch Therapeutics Group Inc Repurchase of Capital Stock (Quarterly) (USD)|Finch Therapeutics Group Inc Ordinary Shares Number (Quarterly)|Finch Therapeutics Group Inc Payout Ratio|Finch Therapeutics Group Inc Quick Ratio (Quarterly)|Finch Therapeutics Group Inc Normalized Diluted EPS (Quarterly) (USD)|Finch Therapeutics Group Inc Stock Buybacks (Quarterly) (USD)|Finch Therapeutics Group Inc Effective Tax Rate (TTM)|Finch Therapeutics Group Inc Return on Equity|Finch Therapeutics Group Inc Net Income (TTM) (USD)|Finch Therapeutics Group Inc Revenue (TTM) (USD)|Finch Therapeutics Group Inc Dividend Per Share (Quarterly) (USD)|Finch Therapeutics Group Inc Revenue (Quarterly) (USD)|Finch Therapeutics Group Inc Gross Profit (Quarterly) (USD)|Finch Therapeutics Group Inc Pre-Tax Income (Quarterly) (USD)|Finch Therapeutics Group Inc Net Income (Quarterly) (USD)|Finch Therapeutics Group Inc Net Interest Income (Quarterly) (USD)|Finch Therapeutics Group Inc Price (USD)|Finch Therapeutics Group Inc Total Return Price (USD)|Finch Therapeutics Group Inc Enterprise Value (USD)|Finch Therapeutics Group Inc 30-Day Average Daily Volume|Finch Therapeutics Group Inc 1 Year Price Returns (Daily)|Finch Therapeutics Group Inc Short Interest|Finch Therapeutics Group Inc PE Ratio (Forward)|Finch Therapeutics Group Inc PE Ratio (Forward 1y)|Finch Therapeutics Group Inc PS Ratio (Forward)|Finch Therapeutics Group Inc PS Ratio (Forward 1y)|Finch Therapeutics Group Inc Quarterly EPS Estimates (USD)|Finch Therapeutics Group Inc Quarterly Revenue Estimates (USD)|Finch Therapeutics Group Inc Quarterly EPS Surprise|Finch Therapeutics Group Inc Quarterly Revenue Surprise|Finch Therapeutics Group Inc Quarterly Actual EPS (USD)|Finch Therapeutics Group Inc Quarterly Actual Revenue (USD)|Finch Therapeutics Group Inc Revenue Estimates for Current Fiscal Year (USD)|Finch Therapeutics Group Inc Revenue Estimates for Next Fiscal Year (USD)|Finch Therapeutics Group Inc Price Target (USD)|Finch Therapeutics Group Inc Consensus Recommendation|Finch Therapeutics Group Inc Price Target Num Estimates|Finch Therapeutics Group Inc EPS Estimates for Current Fiscal Year (USD)|Finch Therapeutics Group Inc EPS Estimates for Next Fiscal Year (USD)|Finch Therapeutics Group Inc Research and Development Expense (Quarterly) (USD)|Finch Therapeutics Group Inc Reconciled Depreciation (Quarterly) (USD)|Finch Therapeutics Group Inc Non-Operating Interest Expense (Quarterly) (USD)|Finch Therapeutics Group Inc Land and Improvements (Quarterly) (USD)|Finch Therapeutics Group Inc Buildings and Improvements (Quarterly) (USD)|Finch Therapeutics Group Inc Other Properties (Quarterly) (USD)|Finch Therapeutics Group Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0505|FNCH|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0505|FNCH|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0505|FNCH|5|91|91||91|91|91|91|91||91|91||1.44206008584|91.5|1.44206008584|91.5|1.44206008584||1.44||91|1.44206008584|91.5|15.3|91|91|91|92||||92|30.6|91.3333333333|91|91.3333333333|91.3333333333|29.125||91|91|91|91.3333333333|91.3333333333|91|92|91|91||91.3333333333||91.3333333333|91.3333333333|91.3333333333|1.44206008584|1.44206008584|1.44206008584|1.44117647059||15.3|||||91|137.5||||91|70.6666666667|70.3333333333|30.2857142857|23.5555555556|30.2857142857|119|90|91.3333333333|91.3333333333||||91|91||
new_0222_0505|FNCH|6|3|3||3|3|3|3|3||3|3||233|2|233|2|233||225||3|233|2|20|3|3|3|1||||1|10|6|3|6|6|8||3|3|3|6|6|3|1|3|3||6||6|6|6|233|233|233|204||20|||||1|2||||1|3|3|7|9|7|1|2|6|6||||3|3||
new_0222_0505|FNCH|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0505|FNCH|202003||||||||||||||||||||||||||||||||||34.692||-0.2277|2.258||||||-0.2277|||||||1.792||-7.901|-7.901|0.091||||||||||||||||||||||||7.397|0.161|||||||
new_0222_0505|FNCH|202006||||||||||||||||||||||||||||||||||34.692||-0.2381|2.574||||||-0.2381|||||||2.349||-8.259|-8.259|0.021||||||||||||||||||||||||8.135|0.208|||||||
new_0222_0505|FNCH|202009||||||||||||||||||||||||||||||||||34.692||-0.2908|2.807||||||-0.2908|||||||1.771||-10.09|-10.09|-0.007||||||||||||||||||||||||9.045|0.205|0.007||||||
new_0222_0505|FNCH|202012|106.164|99.71||7.004|50.957|261.056|11.486|249.57||-95.718|-102.835||||||||||-0.0189||||1.095|2.887|0.008|||||||45.8954|131|-0.2852|6.372|||45.8954||8.7763|-0.285||||-39.341|7.719||1.807||-13.091|-13.091|0.001||||||||||||||||||||||||8.567|0.216||||2.363|1.892||
new_0222_0505|FNCH|202103|198.341|193.023||16.437|50.957|26.494|11.503|14.991||239.457|-116.816||60.2854|-12.5824|-10.9975|2.1489|55.0738||3.1852||0.0076||-15.5819|0.982|2.303|4.198|0.047||||||18.6891|14.0333|165|-1|4.552|47.2273||47.2273||16.9804|-1|-118.575|||-45.421|9.48||3.553||-13.981|-13.981|-0.001|16.15|16.15|571.5059|233691.9333||463769|||||-0.24|||||3.553|5|5|29.3333|1|3|-4.4|-7.715|12.975|0.368||||2.861|5.7|14|14.59
new_0222_0505|FNCH|202106|177.003|168.136||18.327|50.957|22.135|9.524|12.611||228.193|-131.985||50.1099|-9.5382|-7.1132|1.994|50.1443||2.9242||||-17.7699|0.7078|2.25|1.727|0.047|-41.8037||||-42.2101|14.4807|47.3799|186|-0.32|5.882|47.4258||47.4258||17.8902|-0.3586|||-42.2101|-52.331|9.961||2.83||-15.169|-15.169|0.007|14.07|14.07|499.145|87000.2667||335689|||||-0.26||-23.0769||-0.32|2.83|||29.3333|1|3|-2|-1.77|13.964|0.617||||3.417|5.756|13.17|14.15
new_0222_0505|FNCH|202109|156.167|149.2||19.546|50.957|13.178|8.851|4.327||219.801|-141.94||23.9449|-8.9607|-5.8644|2.0075|25.7487||2.8067||||-19.2206|0.5022|2.399|1.382|0.047|-35.0692||||-35.2835|19.1504|47.4452|191|-0.21|5.739|47.455||47.455||17.1279|-0.21|||-35.2835|-52.196|19.533||11.343||-9.955|-9.955|0.008|13|13|467.715|35146.9667||238329|||||||||||20.213||29.6667|1|3||-2.08|15.537|0.638||||3.768|5.787|13.4|16.62
new_0222_0505|FNCH|202112|||||||||||||16.5956||-4.0645||19.7473||2.1536|||||0.5348|||||||||20.3767||||||||||||||||||||||9.97|9.97|324.1626|161294.9667||253910||||||5|||||||||||||||||||8.48|8.71